• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计划生育中的女性生育力保存:意大利生育与不育及生殖医学学会(SIFES-MR)的立场声明

Female fertility preservation for family planning: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR).

作者信息

Massarotti Claudia, Cimadomo Danilo, Spadoni Valentina, Conforti Alessandro, Zacà Carlotta, Carosso Andrea Roberto, Vaiarelli Alberto, Venturella Roberta, Vitagliano Amerigo, Busnelli Andrea, Cozzolino Mauro, Borini Andrea

机构信息

Physiopathology of Human Reproduction, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi, 10, 16132, Genova, Italy.

Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI Department), University of Genova, Genova, Italy.

出版信息

J Assist Reprod Genet. 2024 Sep;41(9):2521-2535. doi: 10.1007/s10815-024-03197-4. Epub 2024 Jul 20.

DOI:10.1007/s10815-024-03197-4
PMID:39030346
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11405660/
Abstract

PURPOSE

This position statement by the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) aims to establish an optimal framework for fertility preservation outside the standard before oncological therapies. Key topics include the role of fertility units in comprehensive fertility assessment, factors impacting ovarian potential, available preservation methods, and appropriate criteria for offering such interventions.

METHODS

The SIFES-MR writing group comprises Italian reproductive physicians, embryologists, and scientists. The consensus emerged after a six-month period of meetings, including extensive literature review, dialogue among authors and input from society members. Final approval was granted by the SIFES-MR governing council.

RESULTS

Fertility counselling transitions from urgent to long-term care, emphasizing family planning. Age, along with ovarian reserve markers, is the primary predictor of female fertility. Various factors, including gynecological conditions, autoimmune disorders, and prior gonadotoxic therapies, may impact ovarian reserve. Oocyte cryopreservation should be the preferred method. Women 30-34 years old and 35-39 years old, without known pathologies impacting the ovarian reserve, should cryopreserve at least 12-13 and 15-20 oocytes to achieve the same chance of a spontaneous live birth they would have if they tried to conceive at the age of cryopreservation (63% and 52%, respectively in the two age groups).

CONCLUSIONS

Optimal fertility counselling necessitates a long-term approach, that nurtures an understanding of fertility, facilitates timely evaluation of factors that may affect fertility, and explores fertility preservation choices at opportune intervals.

摘要

目的

意大利生育与不育及生殖医学学会(SIFES-MR)的这份立场声明旨在建立一个肿瘤治疗前标准之外的生育力保存的最佳框架。关键主题包括生育力单位在全面生育力评估中的作用、影响卵巢潜能的因素、可用的保存方法以及提供此类干预的适当标准。

方法

SIFES-MR写作小组由意大利生殖医生、胚胎学家和科学家组成。经过为期六个月的会议达成共识,包括广泛的文献综述、作者之间的对话以及社会成员的意见。最终由SIFES-MR理事会批准。

结果

生育咨询从紧急护理转变为长期护理,强调计划生育。年龄以及卵巢储备标志物是女性生育力的主要预测指标。包括妇科疾病、自身免疫性疾病和先前的性腺毒性治疗在内的各种因素可能会影响卵巢储备。卵母细胞冷冻保存应是首选方法。30 - 34岁和35 - 39岁且无已知影响卵巢储备的病理情况的女性,应分别冷冻保存至少12 - 13枚和15 - 20枚卵母细胞,以获得与她们在冷冻保存时尝试受孕相同的自然活产机会(两个年龄组分别为63%和52%)。

结论

最佳的生育咨询需要一种长期方法,这种方法能培养对生育力的理解,便于及时评估可能影响生育力的因素,并在适当的时候探索生育力保存选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a7/11405660/28ce7d313eec/10815_2024_3197_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a7/11405660/082131eefd33/10815_2024_3197_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a7/11405660/28ce7d313eec/10815_2024_3197_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a7/11405660/082131eefd33/10815_2024_3197_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/16a7/11405660/28ce7d313eec/10815_2024_3197_Fig2_HTML.jpg

相似文献

1
Female fertility preservation for family planning: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR).计划生育中的女性生育力保存:意大利生育与不育及生殖医学学会(SIFES-MR)的立场声明
J Assist Reprod Genet. 2024 Sep;41(9):2521-2535. doi: 10.1007/s10815-024-03197-4. Epub 2024 Jul 20.
2
Oocyte cryopreservation review: outcomes of medical oocyte cryopreservation and planned oocyte cryopreservation.卵母细胞冷冻保存综述:医学卵母细胞冷冻保存和计划卵母细胞冷冻保存的结果。
Reprod Biol Endocrinol. 2022 Jan 7;20(1):10. doi: 10.1186/s12958-021-00884-0.
3
A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up.一项针对因肿瘤和非肿瘤原因接受生育力保存的女性和女孩的前瞻性研究——瑞典:在长期随访后,患者选择和所选择方法获益的趋势。
Acta Obstet Gynecol Scand. 2019 May;98(5):604-615. doi: 10.1111/aogs.13559. Epub 2019 Mar 18.
4
[Fertility preservation techniques in women of reproductive age ].[育龄期女性的生育力保存技术]
Rev Med Suisse. 2014 Oct 22;10(447):1961-2, 1964-6, 1968.
5
Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives.巴塞罗那国际生育力保护学会-ESHRE-ASRM 2015 专家会议:生育力保存的最新进展:适应证、结果和未来展望。
Hum Reprod. 2017 Sep 1;32(9):1802-1811. doi: 10.1093/humrep/dex218.
6
Beyond fertility preservation: role of the oncofertility unit in the reproductive and gynecological follow-up of young cancer patients.超越生育力保存:oncofertility 单位在年轻癌症患者生殖和妇科随访中的作用。
Hum Reprod. 2019 Aug 1;34(8):1462-1469. doi: 10.1093/humrep/dez108.
7
In vitro maturation of human immature oocytes for fertility preservation.人未成熟卵母细胞的体外成熟用于生育力保存。
Fertil Steril. 2013 Apr;99(5):1173-81. doi: 10.1016/j.fertnstert.2013.01.141. Epub 2013 Feb 20.
8
Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients.预测选择性卵母细胞冷冻保存活产的可能性:为医生和患者提供的咨询工具。
Hum Reprod. 2017 Apr 1;32(4):853-859. doi: 10.1093/humrep/dex008.
9
Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives.巴塞罗那国际生育力保护协会-欧洲人类生殖与胚胎学会-美国生殖医学学会 2015 年专家会议:生育力保存的现状:适应证、结果与未来展望。
Fertil Steril. 2017 Sep;108(3):407-415.e11. doi: 10.1016/j.fertnstert.2017.05.024. Epub 2017 Jul 21.
10
Fertility preservation in childhood and adolescent female tumor survivors.儿童和青少年女性肿瘤幸存者的生育力保存。
Fertil Steril. 2021 Oct;116(4):1087-1095. doi: 10.1016/j.fertnstert.2021.06.012. Epub 2021 Jul 5.

引用本文的文献

1
Fertility preservation in young patients with breast cancer: insights from the Gemme Dormienti network.年轻乳腺癌患者的生育力保存:来自Gemme Dormienti网络的见解
Ther Adv Med Oncol. 2025 Jul 13;17:17588359251341210. doi: 10.1177/17588359251341210. eCollection 2025.
2
"Forever fertile": ovarian tissue cryopreservation for an extended reproductive lifespan.“永葆生育力”:卵巢组织冷冻保存以延长生殖寿命
J Assist Reprod Genet. 2025 Jun 28. doi: 10.1007/s10815-025-03554-x.

本文引用的文献

1
Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI.ART 在预测高反应者中的临床结局:卵母细胞体外成熟与 IVF/ICSI 的常规卵巢刺激。
Hum Reprod. 2024 Mar 1;39(3):586-594. doi: 10.1093/humrep/dead273.
2
Utilization of Cryopreserved Oocytes in Patients With Poor Ovarian Response After Planned Oocyte Cryopreservation.计划冷冻卵子后卵巢反应不良患者的冻卵利用。
JAMA Netw Open. 2024 Jan 2;7(1):e2349722. doi: 10.1001/jamanetworkopen.2023.49722.
3
A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation.
选择性卵母细胞冷冻保存后尝试生育的女性的 10 年生殖结局随访。
Hum Reprod. 2024 Feb 1;39(2):355-363. doi: 10.1093/humrep/dead267.
4
Oocyte cryopreservation with in vitro maturation for fertility preservation in girls at risk for ovarian insufficiency.卵母细胞冷冻保存联合体外成熟用于有卵巢储备功能降低风险的女童生育力保存。
J Assist Reprod Genet. 2023 Dec;40(12):2777-2785. doi: 10.1007/s10815-023-02932-7. Epub 2023 Sep 16.
5
Follicle Stimulating Hormone (FSH) as a Predictor of Decreased Oocyte Yield in Patients with Normal Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC).促卵泡生成素(FSH)作为抗苗勒管激素(AMH)和窦卵泡计数(AFC)正常的患者卵母细胞产量降低的预测指标。
J Reprod Infertil. 2023 Jul-Sep;24(3):181-187. doi: 10.18502/jri.v24i3.13274.
6
Comparison of anti-Müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis.抗苗勒管激素与窦卵泡计数预测卵巢反应的比较:系统评价和荟萃分析。
J Ovarian Res. 2023 Jun 27;16(1):117. doi: 10.1186/s13048-023-01202-5.
7
An epigenetic synopsis of parental substance use.父母物质使用的表观遗传学概述。
Epigenomics. 2023 Apr;15(7):453-473. doi: 10.2217/epi-2023-0064. Epub 2023 Jun 7.
8
Reproductive toxicity of combined effects of endocrine disruptors on human reproduction.内分泌干扰物联合作用对人类生殖的生殖毒性
Front Cell Dev Biol. 2023 May 12;11:1162015. doi: 10.3389/fcell.2023.1162015. eCollection 2023.
9
Fertility preservation in women with benign gynaecological conditions.患有良性妇科疾病女性的生育力保存
Hum Reprod Open. 2023 Apr 6;2023(2):hoad012. doi: 10.1093/hropen/hoad012. eCollection 2023.
10
Clinical and laboratory key performance indicators in IVF: A consensus between the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) and the Italian Society of Embryology, Reproduction and Research (SIERR).辅助生殖技术中临床和实验室关键绩效指标:意大利生育与不育学会(SIFES-MR)和意大利胚胎学、生殖与研究学会(SIERR)的共识
J Assist Reprod Genet. 2023 Jun;40(6):1479-1494. doi: 10.1007/s10815-023-02792-1. Epub 2023 Apr 24.